Would you consider adjuvant olaparib in a premenopausal female with TNBC with high risk features and germline BRCA1 mutation who achieved pCR after neoadjuvant chemotherapy?

I would not, as these patients were not allowed to go on OlympiA. Their residual risk of TNBC relapse after PCR is low so the absolute benefit of olaparib for a year (if any) is also going to be low.